Glenmark Life Sciences make lukewarm debut on exchanges: Share listed as per Anil Singhvi’s expectations- Check details

As analysed by Zee Business Managing Editor Anil Singhvi, Glenmark Life Sciences made a tepid market debut with neither bumper nor weak listing on bourses on Friday. The shares of Glenmark Pharmaceutical arm were listed at a 4 per cent premium on both NSE and BSE to Rs 750 and Rs 751 apiece respectively. 

Singhvi during the company’s initial public offer review had said the listing wouldn’t be below issue price nor spectacular/bumper, perhaps. However, he had suggested investors to apply for the IPO of Glenmark Life Sciences, pointing out that the valuations of the company are reasonable.

See Zee Business Live TV Streaming Below:

The three-day IPO of Glenmark Life had begun on July 27 and closed on July 29, 2021. The price band was fixed at Rs 695-720 per share and a retail investor can bid for a total of 13 lots. 

The IPO will have a fresh issue of equity shares worth up to Rs 1,060 crore and sale of up to 63 lakh equity shares by Glenmark Pharma. The IPO will fetch Rs 1,513.6 crore at the upper price band.

ग्लेनमार्क लाइफ साइंसेज के IPO में क्या करें?

लिस्टिंग पर बनेगा पैसा या लंबी अवधि के लिए लगाएं पैसे?

IPO पर क्या है अनिल सिंघवी की राय?#IPOUpdate #GlenmarkLifeSciences #GlenmarkLifeSciences #IPO @AnilSinghvi_ @NSE @BSEIndia pic.twitter.com/DP2zPgUcTH

— Zee Business (@ZeeBusiness) July 27, 2021

The stock made and high of Rs 800 per share on BSE, while Rs 799 per share on the BSE, while starting its stock market journey on Friday.

Glenmark Life Sciences IPO was oversubscribed by 44.17 times on the final day of subscription on July 29, 2021, it received bids for 66,33,24,160 shares against 1,50,18,279 shares offered, according to the data available on exchanges. 

Qualified Institutional Buyers(QIBs) portion was subscribed 36.97 times, non-institutional investors a queued most with 122.54 times and retail individual investors (RIIs) subscribed by 14.63 times. The company on July 26, 2021, had raised Rs 454 crore from anchor investors, a day before IPO launch.

Glenmark Life Sciences is a leading developer and manufacturer of select high-value, non-commoditised active pharmaceutical ingredients (APIs) in chronic therapeutic areas, including cardiovascular disease, central nervous system disease, pain management, and diabetes.